A group of Massachusetts General Hospital (MGH) investigators is proposing that targeting immune checkpoints – molecules that regulate the activity of the immune system – in immune cells called microglia could reduce the inflammatory aspects of important neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). In their review article published in the October issue of Nature Neuroscience, they discuss how uncontrolled activity of microglia contributes to neurodegeneration in these and other neurodegenerative conditions.
“Microglia have three essential functions: a ‘sentinel’ function that surveys and senses changes within the brain, a ‘nurturer’ function that promotes neuronal wellbeing through actions such as removing dying cells and debris, and a ‘warrior’ function that defends the brain against infections and toxins,” explains Joseph El Khoury, MD, of the MGH Center for Immunology and Inflammatory Diseases and the Division of Infectious Diseases, senior author of the report. “In healthy brains, immune checkpoints in microglia keep the ‘warrior’ function in check. Disruption of those checkpoints initiates or propagates neurodegeneration.”
While microglia have long been recognized as the innate immune cells of the brain, the MGH team is the first to delineate these three functions, based on patterns of gene expression within the cells. After detailing how microglia carry out these functions, the authors review how the processes can go awry in several neurodegenerative disorders:
- In Alzheimer’s disease, microglia are known to accumulate around amyloid-beta plaques, and mutations in several microglial genes can increase the risk of developing the disease. An inability of microglia to keep up with persistent production of amyloid-beta leads to the release of inflammatory factors that further compromise the cells’ ‘nurturer’ functions, eventually transforming them into a disease-associated form that induces persistent, damaging neuroinflammation;
- In Parkinson’s disease, activated microglia are known to be abundant in the substantia nigra, the brain structure that is damaged in the disease. PET studies have shown widespread inflammatory microglia early in the course of the disease, and evidence suggests that the same sort of ‘double-edged sword’ situation seen in Alzheimer’s disease – in which initially protective microglia escape regulation, leading to persistent damaging neuroinflammation – also occurs in Parkinson’s.
- In ALS, inflammatory microglia have been found near injured neurons in the brain of patients. In a mouse model carrying a mutant SOD1 gene – one of several genes that, when mutated, can cause inherited forms of ALS – microglia have been found to be protective at disease onset but neurotoxic at later stages..
The investigators also describe how initially protective microglia can escape regulation and become damaging in multiple sclerosis, Huntington’s disease, and several other neurodegenerative conditions.
The team identifies three potential immune checkpoints in microglia – Trem2, which regulates all three functions; Cx3cr1, which regulates the sentinel and nurturer functions, and the progranulin pathway, which also regulates sentinel and nurturer functions. Evidence points to dysregulation of both Trem2 and progranulin in Alzheimer’s disease, ALS and other disorders; and Cx3cr1 is known to alter the course of disease in animal models of Alzheimer’s disease, Parkinson’s disease, ALS and other disorders.
While immune checkpoint therapies for cancer – discovery of which recently received the Nobel Prize in Medicine – are designed to inhibit checkpoints that prevent the immune system from attacking tumor cells, in neurodegenerative disease the goal would be to activate checkpoints that could reduce and potentially eliminate out-of-control neuroinflammation, returning microglia to their healthy neuroprotective state. El Khoury and his colleagues are now working to improve understanding of how microglia contribute to neurodegeneration.
“Analyzing patterns of microglial gene transcription and regulation in several disease states, understanding how those patterns may be altered by aging and disease progression, and correlating those changes to microglial behavior is essential,” he says. “Expanding studies from animal models to human patients remains a challenge that will require development of new, reliable cellular models based on patient samples and additional technologies for imaging and analysis. And new techniques to incorporate microglia into three-dimensional organoids – miniature organs grown from living tissues – are a crucial next breakthrough that needs to be achieved.” El Khoury is an associate professor of Medicine at Harvard Medical School.
Suzanne Hickman, PhD, of the MGH Center for Immunology and Inflammatory Diseases is lead author of the Nature Neuroscience report. Additional co-authors are Saef Izzy, MD, Pritha Sen, MD, and Liza Morsett, all of the Center for Immunology and Inflammatory Diseases. The article was prepared through support from National Institutes of Health grant RF1 AG051506.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $900 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2018 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."
Media contact: Terri Ogan, email@example.com, 617 726-0954